Clinical Trials Logo
  1. Home
  2. Colitis
  3. NCT05947669

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis — iCaD  

Colitis Clinical Trial

Official title:
Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study

Clinical Trial Summary

The goal of this clinical trial is to assess whether the early introduction of biological treatment with a TNF-alpha inhibitor (infliximab) in addition to corticosteroids for severe ir-colitis/diarrhoea will reduce the time to grade ≤ 1 ir-colitis/diarrhoea compared to corticosteroids alone in patients scheduled for ICI treatment for solid tumors and untreated mCTCAE grade 2-4 diarrhoea or colitis. The main question it aims to answer is: • Can an early introduction of biological treatment with a TNF-alpha inhibitor (infliximab) in addition to corticosteroids reduce the time to grade ≤ 1 ir-colitis/diarrhoea compared to corticosteroids alone. Participants will be randomised 1:1: Arm A: All patients will receive same dose of methylprednisolone i.v. daily. Arm B: Patients allocated to Arm B will in addition receive infliximab i.v. day 1 or 2. Study patients are evaluated with blood samples, faecal samples and by sigmoidoscopy. Procedures are performed before randomisation and as part of follow up.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05947669
Study type Interventional
Source Odense University Hospital
Contact Sören K. Petersen, MD
Phone 0045 2046 5726
Email soeren.kjaer@rsyd.dk
Status Recruiting
Phase Phase 3
Start date August 22, 2023
Completion date September 2028
View Details
See also
  Status Clinical Trial Phase
Completed NCT00272818 - Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
Completed NCT01369355 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Phase 3
Completed NCT02709213 - Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
Completed NCT00533078 - Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies Phase 2
Terminated NCT00184171 - Treatment of Microscopic Colitis N/A
Recruiting NCT05333978 - Optoacoustic Detection of Inflammation Using MSOT Device N/A
Not yet recruiting NCT06424769 - Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management N/A
Recruiting NCT02768038 - Intestinal Microbiome and Chronic Inflammatory Bowel Disease
Recruiting NCT04272307 - MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
Completed NCT05514561 - FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
Completed NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease Phase 2
Recruiting NCT02687724 - Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis Phase 4
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT01326013 - A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel Phase 2
Not yet recruiting NCT05726396 - A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis Phase 2
Completed NCT05414552 - ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Recruiting NCT04407247 - Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma Phase 1/Phase 2
Completed NCT01369329 - A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) Phase 3
Completed NCT01369342 - A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) Phase 3
Terminated NCT00936585 - NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease N/A